Cote named as FDA director of orphan product development

WASHINGTON The Food and Drug Administration has named Dr. Timothy Cote, as its new director of Office of Orphan Product Development.

Cote, whose experience ranges from medical epidemiology to clinical research, has worked for the FDA before as its chief of the Therapeutics and Blood Safety Branch in the Center for Biologics Evaluation and Research, office of Biostatistics and Epidemiology.

“We are very pleased to have Dr. Cote rejoin the FDA as the new head of the Orphan Products Development office,” said Janet Woodcock, deputy commissioner for the FDA. “Tim brings a plethora of experience confronting emerging health issues in the United States and abroad, coupled with a commitment to public service.”

He earned his medical degree from Howard University College of Medicine and a masters in public health from the Harvard School of Public Health.